87 related articles for article (PubMed ID: 18445521)
21. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
Wang Z; Sinha BK
Mol Pharmacol; 1996 Feb; 49(2):269-75. PubMed ID: 8632759
[TBL] [Abstract][Full Text] [Related]
23. Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response.
Zuco V; Benedetti V; De Cesare M; Zunino F
Int J Cancer; 2010 Mar; 126(5):1246-55. PubMed ID: 19676051
[TBL] [Abstract][Full Text] [Related]
24. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Whitacre CM; Zborowska E; Willson JK; Berger NA
Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720
[TBL] [Abstract][Full Text] [Related]
25. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies.
Caiolfa VR; Zamai M; Fiorino A; Frigerio E; Pellizzoni C; d'Argy R; Ghiglieri A; Castelli MG; Farao M; Pesenti E; Gigli M; Angelucci F; Suarato A
J Control Release; 2000 Mar; 65(1-2):105-19. PubMed ID: 10699275
[TBL] [Abstract][Full Text] [Related]
26. Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.
De Cesare M; Lauricella C; Veronese SM; Cominetti D; Pisano C; Zunino F; Zaffaroni N; Zuco V
Clin Cancer Res; 2014 Feb; 20(4):995-1006. PubMed ID: 24327272
[TBL] [Abstract][Full Text] [Related]
27. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
[TBL] [Abstract][Full Text] [Related]
28. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
29. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
30. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
32. Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.
Lansiaux A; Bras-Goncalves RA; Rosty C; Laurent-Puig P; Poupon MF; Bailly C
Anticancer Res; 2001; 21(1A):471-6. PubMed ID: 11299781
[TBL] [Abstract][Full Text] [Related]
33. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy.
Bhattacharya A; Tóth K; Mazurchuk R; Spernyak JA; Slocum HK; Pendyala L; Azrak R; Cao S; Durrani FA; Rustum YM
Clin Cancer Res; 2004 Dec; 10(23):8005-17. PubMed ID: 15585636
[TBL] [Abstract][Full Text] [Related]
34. Use of irinotecan for treatment of small cell carcinoma of the prostate.
Tung WL; Wang Y; Gout PW; Liu DM; Gleave M; Wang Y
Prostate; 2011 May; 71(7):675-81. PubMed ID: 20949523
[TBL] [Abstract][Full Text] [Related]
35. Establishment of human prostate tumor xenografts in nude mice and response to 9-nitrocamptothecin in vivo and in vitro does not correlate with the expression of various apoptosis-regulating proteins.
Pantazis P; Chatterjee D; Wyche J; DeJesus A; Early J; Plaschke S; Giovanella B
J Exp Ther Oncol; 1996 Sep; 1(5):322-33. PubMed ID: 9414421
[TBL] [Abstract][Full Text] [Related]
36. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
Motwani M; Jung C; Sirotnak FM; She Y; Shah MA; Gonen M; Schwartz GK
Clin Cancer Res; 2001 Dec; 7(12):4209-19. PubMed ID: 11751522
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of antitumor activity of etoposide administered orally for 21 consecutive days against human uterine cancer subcutaneous and/or orthotopic xenografts in nude mice].
Matsumoto S; Mashiba H; Okamoto K; Ekimoto H
Gan To Kagaku Ryoho; 1999 Aug; 26(9):1313-20. PubMed ID: 10478185
[TBL] [Abstract][Full Text] [Related]
38. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth.
Bhonde MR; Hanski ML; Notter M; Gillissen BF; Daniel PT; Zeitz M; Hanski C
Oncogene; 2006 Jan; 25(2):165-75. PubMed ID: 16170360
[TBL] [Abstract][Full Text] [Related]
39. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
40. Camptothecin poly[n-(2-hydroxypropyl) methacrylamide] copolymers in antitopoisomerase-I tumor therapy: intratumor release and antitumor efficacy.
Zamai M; VandeVen M; Farao M; Gratton E; Ghiglieri A; Castelli MG; Fontana E; D'Argy R; Fiorino A; Pesenti E; Suarato A; Caiolfa VR
Mol Cancer Ther; 2003 Jan; 2(1):29-40. PubMed ID: 12533670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
